Bristol Myers Squibb (CELG-RI) Assets (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Assets of $87.6 billion for Q2 2026, down 7.44% year-over-year from $94.7 billion in Q2 2025, and up 1.34% quarter-over-quarter from $86.5 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Assets (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Assets for 18 consecutive years, with $87.6 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets fell 7.44% year-over-year to $87.6 billion; the TTM figure through Jun 2026 stood at $87.6 billion (down 7.44% YoY), while the FY2025 annual figure was $90.0 billion, down 2.77% from the prior year.
- Assets climbed to $87.6 billion in Q2 2026 per CELG-RI's latest filing, from $86.5 billion in the prior quarter.
- Across five years, Assets topped out at $103.0 billion in Q1 2022 and bottomed at $86.5 billion in Q1 2026.
- Historically, Assets has averaged $94.5 billion across 5 years, with a median of $94.5 billion in 2023.
- Annual changes were most pronounced in 2022 — Assets dropped 11.45% — and 2024, when it gained 5.04%.
- Bristol Myers Squibb's Assets stood at $96.8 billion in 2022, then fell by 1.72% to $95.2 billion in 2023, then fell by 2.69% to $92.6 billion in 2024, then declined by 2.77% to $90.0 billion in 2025, then decreased by 2.67% to $87.6 billion in 2026.
- Business Quant data shows CELG-RI's Assets at $87.6 billion in Q2 2026, $86.5 billion in Q1 2026, and $90.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.18 Bn | 632.42 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 470.13 Bn | 463.56 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 376.16 Bn | 369.02 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 302.69 Bn | 295.00 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 257.73 Bn | 252.83 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 236.53 Bn | 222.54 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 183.21 Bn | 180.03 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 160.17 Bn | 148.47 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Gsk | 105.91 Bn | 101.75 Bn | 8.24 Bn | 82.83 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 87.63 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87.63 Bn |
| Mar 31, 2026 | 86.48 Bn |
| Dec 31, 2025 | 90.04 Bn |
| Sep 30, 2025 | 96.89 Bn |
| Jun 30, 2025 | 94.68 Bn |
| Mar 31, 2025 | 92.43 Bn |
| Dec 31, 2024 | 92.60 Bn |
| Sep 30, 2024 | 93.67 Bn |
| Jun 30, 2024 | 94.65 Bn |
| Mar 31, 2024 | 99.03 Bn |
| Dec 31, 2023 | 95.16 Bn |
| Sep 30, 2023 | 91.26 Bn |
| Jun 30, 2023 | 93.49 Bn |
| Mar 31, 2023 | 94.28 Bn |
| Dec 31, 2022 | 96.82 Bn |
| Sep 30, 2022 | 98.20 Bn |
| Jun 30, 2022 | 100.36 Bn |
| Mar 31, 2022 | 103.03 Bn |
| Dec 31, 2021 | 109.31 Bn |
| Sep 30, 2021 | 110.89 Bn |